Rhumbline Advisers Anavex Life Sciences Corp. Transaction History
Rhumbline Advisers
- $109 Billion
- Q4 2024
A detailed history of Rhumbline Advisers transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Rhumbline Advisers holds 123,699 shares of AVXL stock, worth $1.08 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
123,699
Previous 120,201
2.91%
Holding current value
$1.08 Million
Previous $682,000
94.72%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding AVXL
# of Institutions
188Shares Held
29.2MCall Options Held
894KPut Options Held
821K-
Black Rock Inc. New York, NY6.39MShares$55.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.68MShares$40.9 Million0.0% of portfolio
-
State Street Corp Boston, MA2.41MShares$21.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.87MShares$16.4 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA1.13MShares$9.91 Million0.0% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $680M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...